Name | Number of supported studies | Average coverage | |
---|---|---|---|
smooth muscle cell | 9 studies | 19% ± 4% | |
fibroblast | 9 studies | 21% ± 8% | |
endothelial cell | 7 studies | 27% ± 10% | |
pericyte | 6 studies | 22% ± 6% | |
ciliated cell | 6 studies | 27% ± 10% | |
connective tissue cell | 5 studies | 22% ± 6% | |
neuron | 5 studies | 33% ± 16% | |
myofibroblast cell | 5 studies | 20% ± 2% | |
retinal ganglion cell | 4 studies | 61% ± 27% | |
amacrine cell | 4 studies | 32% ± 16% | |
glutamatergic neuron | 3 studies | 42% ± 18% | |
epithelial cell | 3 studies | 33% ± 9% | |
retina horizontal cell | 3 studies | 28% ± 12% | |
oligodendrocyte precursor cell | 3 studies | 22% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 2121.85 | 258 / 258 | 100% | 50.20 | 230 / 230 |
ovary | 100% | 3852.18 | 180 / 180 | 100% | 53.64 | 430 / 430 |
thymus | 100% | 3315.35 | 653 / 653 | 100% | 43.38 | 605 / 605 |
brain | 100% | 5954.87 | 2641 / 2642 | 100% | 65.19 | 705 / 705 |
prostate | 100% | 3307.24 | 245 / 245 | 99% | 28.65 | 498 / 502 |
skin | 100% | 1644.92 | 1802 / 1809 | 99% | 26.40 | 469 / 472 |
breast | 100% | 2557.55 | 459 / 459 | 98% | 24.98 | 1097 / 1118 |
kidney | 99% | 2619.22 | 88 / 89 | 99% | 24.87 | 891 / 901 |
uterus | 100% | 3377.42 | 170 / 170 | 96% | 28.20 | 441 / 459 |
liver | 95% | 2097.11 | 215 / 226 | 97% | 28.36 | 394 / 406 |
lung | 99% | 1887.53 | 574 / 578 | 91% | 16.15 | 1055 / 1155 |
bladder | 100% | 2735.43 | 21 / 21 | 83% | 18.82 | 418 / 504 |
pancreas | 80% | 757.30 | 261 / 328 | 96% | 20.63 | 170 / 178 |
esophagus | 93% | 2153.47 | 1348 / 1445 | 72% | 11.75 | 131 / 183 |
stomach | 97% | 1535.37 | 348 / 359 | 53% | 7.34 | 153 / 286 |
intestine | 92% | 2189.18 | 892 / 966 | 41% | 5.58 | 215 / 527 |
eye | 0% | 0 | 0 / 0 | 100% | 30.18 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 14.71 | 29 / 29 |
spleen | 100% | 2615.50 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 45.32 | 1 / 1 |
blood vessel | 100% | 2978.52 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 2411.04 | 1202 / 1204 | 0% | 0 | 0 / 0 |
heart | 99% | 1723.75 | 849 / 861 | 0% | 0 | 0 / 0 |
muscle | 97% | 1297.14 | 776 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 80% | 16.54 | 36 / 45 |
peripheral blood | 48% | 524.82 | 447 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006351 | Biological process | DNA-templated transcription |
GO_0006368 | Biological process | transcription elongation by RNA polymerase II |
GO_0006354 | Biological process | DNA-templated transcription elongation |
GO_0032784 | Biological process | regulation of DNA-templated transcription elongation |
GO_0005813 | Cellular component | centrosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0008023 | Cellular component | transcription elongation factor complex |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0005515 | Molecular function | protein binding |
GO_0008270 | Molecular function | zinc ion binding |
Gene name | TCEA2 |
Protein name | Transcription elongation factor A protein 2 (SII) Transcription elongation factor A2 Transcription elongation factor TCEA2 protein (Transcription elongation factor A (SII), 2, isoform CRA_b) (Transcription elongation factor A2) Transcription elongation factor A protein 2 (Testis-specific S-II) (Transcription elongation factor S-II protein 2) (Transcription elongation factor TFIIS.l) |
Synonyms | hCG_2021465 |
Description | FUNCTION: Necessary for efficient RNA polymerase II transcription elongation past template-encoded arresting sites. The arresting sites in DNA have the property of trapping a certain fraction of elongating RNA polymerases that pass through, resulting in locked ternary complexes. Cleavage of the nascent transcript by S-II allows the resumption of elongation from the new 3'-terminus. . FUNCTION: Necessary for efficient RNA polymerase II transcription elongation past template-encoded arresting sites. The arresting sites in DNA have the property of trapping a certain fraction of elongating RNA polymerases that pass through, resulting in locked ternary complexes. Cleavage of the nascent transcript by S-II allows the resumption of elongation from the new 3'-terminus. . FUNCTION: Necessary for efficient RNA polymerase II transcription elongation past template-encoded arresting sites. . FUNCTION: Necessary for efficient RNA polymerase II transcription elongation past template-encoded arresting sites. The arresting sites in DNA have the property of trapping a certain fraction of elongating RNA polymerases that pass through, resulting in locked ternary complexes. Cleavage of the nascent transcript by S-II allows the resumption of elongation from the new 3'-terminus. . |
Accessions | ENST00000440819.5 ENST00000343484.10 [Q15560-1] Q86VL0 Q5JRI7 ENST00000415602.5 ENST00000395053.7 Q5ZEZ5 ENST00000458442.1 ENST00000361317.6 [Q15560-2] Q15560 ENST00000339217.8 Q6IB64 Q5JRI8 A0A0A0MT58 |